{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,3,8]],"date-time":"2024-03-08T00:22:39Z","timestamp":1709857359220},"reference-count":17,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2023,11,20]],"date-time":"2023-11-20T00:00:00Z","timestamp":1700438400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,3,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Purpose<\/jats:title>\n                  <jats:p>Our community hospital was recently charged with providing care for pediatric people with cystic fibrosis (PwCF). Pediatric PwCF generally need a higher level of care than is required by other pediatric patients cared for at our institution. This project aimed to prepare the pharmacy department to care for this specialized population safely and efficiently.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Summary<\/jats:title>\n                  <jats:p>The implementation process was divided into 3 phases to accomplish the larger purpose. These phases were as follows: (1) creating order sets and protocols; (2) providing staff and clinical pharmacists with training and resources; and (3) creating and managing clinical decision support. The central aspect of preparing inpatient pharmacy staff to care for PwCF was the development of antibiotic dosing protocols and order sets comprised of intravenous and oral antibiotics as well as aminoglycoside and vancomycin pharmacokinetic guides. A pharmacokinetic calculator was created to assist with aminoglycoside dosing and monitoring. During phase 2, pharmacist education modules were created to provide guidance on cystic fibrosis and medications commonly used to treat it. As the newly designed protocols were enacted, education was provided on how to use them. Phase 3 occurred concurrently, as clinical decision support was vital to completing phases 1 and 2.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>The phased approach was imperative to the project\u2019s success and kept individual components on track. All parts were completed in just over one year.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ajhp\/zxad287","type":"journal-article","created":{"date-parts":[[2023,11,17]],"date-time":"2023-11-17T23:19:46Z","timestamp":1700263186000},"page":"219-225","source":"Crossref","is-referenced-by-count":0,"title":["Implementing services for pediatric cystic fibrosis treatment in a community hospital"],"prefix":"10.1093","volume":"81","author":[{"given":"Paige","family":"Grube","sequence":"first","affiliation":[{"name":"Cincinnati Children\u2019s Hospital Medical Center , Cincinnati, OH , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heather","family":"Nichols","sequence":"additional","affiliation":[{"name":"Parkview Regional Medical Center , Fort Wayne, IN , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Ferrell","sequence":"additional","affiliation":[{"name":"Parkview Regional Medical Center , Fort Wayne, IN , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Denise","family":"Gilham","sequence":"additional","affiliation":[{"name":"Pediatric Pulmonary, CF, and Abnormal Newborn Screen Program, Parkview Regional Medical Center , Fort Wayne, IN , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Allyson","family":"Gaylor","sequence":"additional","affiliation":[{"name":"Parkview Regional Medical Center , Fort Wayne, IN , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen","family":"Dunkelberger","sequence":"additional","affiliation":[{"name":"Parkview Regional Medical Center , Fort Wayne, IN , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2023,11,20]]},"reference":[{"issue":"2","key":"2024030715444748800_CIT0001","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1542\/pir.2019-0212","article-title":"Cystic fibrosis","volume":"42","author":"Dickinson","year":"2021","journal-title":"Pediatr Rev"},{"issue":"10","key":"2024030715444748800_CIT0002","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1164\/rccm.201910-1943SO","article-title":"Cystic fibrosis: emergence of highly effective targeted therapeutics and potential clinical implications","volume":"201","author":"Mall","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"key":"2024030715444748800_CIT0003","author":"Cystic Fibrosis Foundation"},{"key":"2024030715444748800_CIT0004","author":"Jordan","year":"2023"},{"key":"2024030715444748800_CIT0005","doi-asserted-by":"crossref","first-page":"S127","DOI":"10.1016\/S1569-1993(15)30443-4","article-title":"269 living with cystic fibrosis in a remote rural area","volume":"14","author":"Jessup","year":"2015","journal-title":"J Cyst Fibros"},{"issue":"4","key":"2024030715444748800_CIT0006","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/j.ccm.2022.06.007","article-title":"The impact of highly effective modulator therapy on cystic fibrosis microbiology and inflammation","volume":"43","author":"Caverly","year":"2022","journal-title":"Clin Chest Med"},{"key":"2024030715444748800_CIT0007","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1002\/ppul.25250","article-title":"Reduction of pulmonary exacerbations in young children with cystic fibrosis during the COVID-19 pandemic","volume":"56","author":"Patel","year":"2021","journal-title":"Pediatr Pulmonol"},{"key":"2024030715444748800_CIT0008","doi-asserted-by":"crossref","first-page":"00588","DOI":"10.1183\/23120541.00588-2021","article-title":"Impact of lockdown during the COVID-19 pandemic on health status in patients with cystic fibrosis: a mono-centre observational study","volume":"8","author":"Thee","year":"2022","journal-title":"ERJ Open Res"},{"key":"2024030715444748800_CIT0009","author":"Cystic Fibrosis Foundation"},{"key":"2024030715444748800_CIT0010","doi-asserted-by":"crossref","first-page":"i3","DOI":"10.1136\/bmjqs-2013-002363","article-title":"Improving chronic care delivery and outcomes: the impact of the cystic fibrosis Care Center Network","volume":"23","author":"Mogayzel","year":"2014","journal-title":"BMJ Qual Saf"},{"key":"2024030715444748800_CIT0011","author":"Cystic Fibrosis Foundation"},{"issue":"19","key":"2024030715444748800_CIT0012","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1001\/jama.2017.17384","article-title":"Pancreatic enzyme replacement products","volume":"318","year":"2017","journal-title":"JAMA"},{"issue":"3","key":"2024030715444748800_CIT0013","first-page":"214","article-title":"A review of extended and continuous infusion beta-lactams in pediatric patients","volume":"27","author":"Imburgia","year":"2022","journal-title":"J Pediatr Pharmacol Ther"},{"key":"2024030715444748800_CIT0014","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1345\/aph.1R216","article-title":"Continuous and extended infusions of beta-lactam antibiotics in the pediatric population","volume":"46","author":"Walker","year":"2012","journal-title":"Ann Pharmacother"},{"issue":"3","key":"2024030715444748800_CIT0015","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1002\/ppul.22667","article-title":"Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: III. fluoroquinolones","volume":"48","author":"Stockmann","year":"2013","journal-title":"Pediatr Pulmonol"},{"key":"2024030715444748800_CIT0016","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.2146\/ajhp100626","article-title":"Development and implementation of an interdisciplinary oncology program in a community hospital","volume":"68","author":"Chung","year":"2011","journal-title":"Am J Health-Syst Pharm"},{"key":"2024030715444748800_CIT0017","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.ajic.2018.06.009","article-title":"Phased antimicrobial stewardship program implemented for a large community hospital system","volume":"47","author":"Burgess","year":"2019","journal-title":"Am J Infect Control"}],"container-title":["American Journal of Health-System Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajhp\/advance-article-pdf\/doi\/10.1093\/ajhp\/zxad287\/54182822\/zxad287.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajhp\/article-pdf\/81\/6\/219\/56874316\/zxad287.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajhp\/article-pdf\/81\/6\/219\/56874316\/zxad287.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,7]],"date-time":"2024-03-07T17:48:17Z","timestamp":1709833697000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajhp\/article\/81\/6\/219\/7429370"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,20]]},"references-count":17,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2023,11,20]]},"published-print":{"date-parts":[[2024,3,7]]}},"URL":"https:\/\/doi.org\/10.1093\/ajhp\/zxad287","relation":{},"ISSN":["1079-2082","1535-2900"],"issn-type":[{"value":"1079-2082","type":"print"},{"value":"1535-2900","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,3,15]]},"published":{"date-parts":[[2023,11,20]]}}}